Journal article
A Prospective Trial Comparing Q-Switched Ruby Laser and a Triple Combination Skin-Lightening Cream in the Treatment of Solar Lentigines.
- Imhof L Department of Dermatology, University Hospital, Zurich, Switzerland.
- Dummer R
- Dreier J
- Kolm I
- Barysch MJ
- 2016-06-25
Published in:
- Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. - 2016
Aged
Dexamethasone
Drug Combinations
Erythema
Female
Hand Dermatoses
Humans
Hydroquinones
Lasers, Solid-State
Lentigo
Male
Middle Aged
Pain
Prospective Studies
Skin Cream
Skin Lightening Preparations
Tretinoin
English
BACKGROUND
Quality-switched (QS) laser therapy is a safe and well-established treatment option for removing solar lentigines. Triple combination therapy (TCT) with the active pharmaceutical ingredients hydroquinone 5%, tretinoin 0.03%, and dexamethasone 0.03% is often used for skin-lightening.
OBJECTIVE
This prospective, open-label trial compares the efficacy and safety of a QS Ruby laser (QSRL) and a TCT in the treatment of solar lentigines.
METHODS
In total, 15 patients with symmetrically distributed solar lentigines on the back of both hands were included. The lesions on the back of the right hand were treated in one or 2 sessions with a QSRL, the ones on the back of the left hand with a TCT for 7 weeks accompanied by UV protection. Clinical results were evaluated 4 weeks, 8 weeks, and 20 weeks after baseline.
RESULTS
Treatment with QSRL provided significant lightening (p = .01) compared with TCT. Both procedures were generally well-tolerated. Comparing the side effects, the laser produced significantly more crusting and hyperpigmentation than the TCT.
CONCLUSION
Both QSRL and TCT were capable in reducing solar lentigines in Fitzpatrick skin Type I to IV with an acceptable side effect profile. The QSRL provides faster, superior, and long lasting lightening compared with TCT.
Quality-switched (QS) laser therapy is a safe and well-established treatment option for removing solar lentigines. Triple combination therapy (TCT) with the active pharmaceutical ingredients hydroquinone 5%, tretinoin 0.03%, and dexamethasone 0.03% is often used for skin-lightening.
OBJECTIVE
This prospective, open-label trial compares the efficacy and safety of a QS Ruby laser (QSRL) and a TCT in the treatment of solar lentigines.
METHODS
In total, 15 patients with symmetrically distributed solar lentigines on the back of both hands were included. The lesions on the back of the right hand were treated in one or 2 sessions with a QSRL, the ones on the back of the left hand with a TCT for 7 weeks accompanied by UV protection. Clinical results were evaluated 4 weeks, 8 weeks, and 20 weeks after baseline.
RESULTS
Treatment with QSRL provided significant lightening (p = .01) compared with TCT. Both procedures were generally well-tolerated. Comparing the side effects, the laser produced significantly more crusting and hyperpigmentation than the TCT.
CONCLUSION
Both QSRL and TCT were capable in reducing solar lentigines in Fitzpatrick skin Type I to IV with an acceptable side effect profile. The QSRL provides faster, superior, and long lasting lightening compared with TCT.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1097/DSS.0000000000000793
- PMID 27341683
- Persistent URL
- https://sonar.ch/global/documents/66590
Statistics
Document views: 13
File downloads: